Caseware UK (AP4) 2024.0.164 2024.0.164 2025-06-30 2025-06-30 The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2024-07-01 false No description of principal activity 36 65 true true false 08927511 2024-07-01 2025-06-30 08927511 2023-07-01 2024-06-30 08927511 2025-06-30 08927511 2024-06-30 08927511 2023-07-01 08927511 c:PriorPeriodIncreaseDecrease 2024-07-01 2025-06-30 08927511 c:PriorPeriodIncreaseDecrease 2023-07-01 2024-06-30 08927511 d:Director5 2024-07-01 2025-06-30 08927511 c:Buildings c:LongLeaseholdAssets 2024-07-01 2025-06-30 08927511 c:Buildings c:LongLeaseholdAssets 2025-06-30 08927511 c:Buildings c:LongLeaseholdAssets 2024-06-30 08927511 c:OfficeEquipment 2024-07-01 2025-06-30 08927511 c:OfficeEquipment 2025-06-30 08927511 c:OfficeEquipment 2024-06-30 08927511 c:OfficeEquipment c:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 08927511 c:ComputerEquipment 2024-07-01 2025-06-30 08927511 c:ComputerEquipment 2025-06-30 08927511 c:ComputerEquipment 2024-06-30 08927511 c:ComputerEquipment c:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 08927511 c:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 08927511 c:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-07-01 2025-06-30 08927511 c:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-06-30 08927511 c:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-06-30 08927511 c:CurrentFinancialInstruments 2025-06-30 08927511 c:CurrentFinancialInstruments 2024-06-30 08927511 c:Non-currentFinancialInstruments 2025-06-30 08927511 c:Non-currentFinancialInstruments 2024-06-30 08927511 c:CurrentFinancialInstruments c:WithinOneYear 2025-06-30 08927511 c:CurrentFinancialInstruments c:WithinOneYear 2024-06-30 08927511 c:Non-currentFinancialInstruments c:AfterOneYear 2025-06-30 08927511 c:Non-currentFinancialInstruments c:AfterOneYear 2024-06-30 08927511 c:Non-currentFinancialInstruments c:BetweenOneTwoYears 2025-06-30 08927511 c:Non-currentFinancialInstruments c:BetweenOneTwoYears 2024-06-30 08927511 c:Non-currentFinancialInstruments c:BetweenTwoFiveYears 2025-06-30 08927511 c:Non-currentFinancialInstruments c:BetweenTwoFiveYears 2024-06-30 08927511 c:ShareCapital 2024-07-01 2025-06-30 08927511 c:ShareCapital 2025-06-30 08927511 c:ShareCapital 2023-07-01 2024-06-30 08927511 c:ShareCapital 2024-06-30 08927511 c:ShareCapital 2023-07-01 08927511 c:SharePremium 2024-07-01 2025-06-30 08927511 c:SharePremium 2025-06-30 08927511 c:SharePremium c:PriorPeriodIncreaseDecrease 2024-07-01 2025-06-30 08927511 c:SharePremium 2023-07-01 2024-06-30 08927511 c:SharePremium 2024-06-30 08927511 c:SharePremium c:PriorPeriodIncreaseDecrease 2023-07-01 2024-06-30 08927511 c:SharePremium 2023-07-01 08927511 c:CapitalRedemptionReserve 2024-07-01 2025-06-30 08927511 c:CapitalRedemptionReserve 2025-06-30 08927511 c:CapitalRedemptionReserve c:PriorPeriodIncreaseDecrease 2024-07-01 2025-06-30 08927511 c:CapitalRedemptionReserve 2023-07-01 2024-06-30 08927511 c:CapitalRedemptionReserve 2024-06-30 08927511 c:CapitalRedemptionReserve c:PriorPeriodIncreaseDecrease 2023-07-01 2024-06-30 08927511 c:CapitalRedemptionReserve 2023-07-01 08927511 c:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30 08927511 c:RetainedEarningsAccumulatedLosses 2025-06-30 08927511 c:RetainedEarningsAccumulatedLosses c:PriorPeriodIncreaseDecrease 2024-07-01 2025-06-30 08927511 c:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 08927511 c:RetainedEarningsAccumulatedLosses 2024-06-30 08927511 c:RetainedEarningsAccumulatedLosses c:PriorPeriodIncreaseDecrease 2023-07-01 2024-06-30 08927511 c:RetainedEarningsAccumulatedLosses 2023-07-01 08927511 c:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-06-30 08927511 c:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-06-30 08927511 d:FRS102 2024-07-01 2025-06-30 08927511 d:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 08927511 d:FullAccounts 2024-07-01 2025-06-30 08927511 d:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 08927511 c:WithinOneYear 2025-06-30 08927511 c:WithinOneYear 2024-06-30 08927511 c:BetweenOneFiveYears 2025-06-30 08927511 c:BetweenOneFiveYears 2024-06-30 08927511 c:DevelopmentCostsCapitalisedDevelopmentExpenditure c:ExternallyAcquiredIntangibleAssets 2024-07-01 2025-06-30 08927511 6 2024-07-01 2025-06-30 08927511 c:DevelopmentCostsCapitalisedDevelopmentExpenditure c:OwnedIntangibleAssets 2024-07-01 2025-06-30 08927511 e:PoundSterling 2024-07-01 2025-06-30 08927511 c:ShareCapital c:PriorPeriodErrorIncreaseDecrease 2024-07-01 2025-06-30 08927511 c:ShareCapital c:PriorPeriodErrorIncreaseDecrease 2023-07-01 2024-06-30 08927511 c:RetainedEarningsAccumulatedLosses c:PreviouslyStatedAmount 2024-06-30 08927511 c:RetainedEarningsAccumulatedLosses c:PreviouslyStatedAmount 2023-07-01 08927511 c:PreviouslyStatedAmount 2024-06-30 08927511 c:PreviouslyStatedAmount 2023-07-01 iso4217:GBP xbrli:pure

Registered number: 08927511 ORCHA HEALTH LIMITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
ORCHA HEALTH LIMITED REGISTERED NUMBER: 08927511 BALANCE SHEET AS AT 30 JUNE 2025
|  |  |  | As restated
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Intangible assets | 4 |  | 1,278,191 |  | 1,908,263
Tangible assets | 5 |  | 1,908 |  | 206,690
Investments | 6 |  | 918 |  | 918
|  |  | 1,281,017 |  | 2,115,871
Current assets |  |  |  |  |
Debtors: amounts falling due after more than one year | 7 | 526,728 |  | 442,447 |
Debtors: amounts falling due within one year | 7 | 75,361 |  | 364,941 |
Cash at bank and in hand | 8 | 42,197 |  | 58,443 |
|  | 644,286 |  | 865,831 |
Creditors: amounts falling due within one year | 9 | (4,096,290) |  | (2,746,102) |
Net current liabilities |  |  | (3,452,004) |  | (1,880,271)
Total assets less current liabilities |  |  | (2,170,987) |  | 235,600
Creditors: amounts falling due after more than one year | 10 |  | (675) |  | (10,813)
Net (liabilities)/assets |  |  | (2,171,662) |  | 224,787
Page 1
ORCHA HEALTH LIMITED REGISTERED NUMBER: 08927511 BALANCE SHEET (CONTINUED) AS AT 30 JUNE 2025
|  |  |  | As restated
|  | 2025 |  | 2024
Note |  | £ |  | £
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 207,563 |  | 207,563
Share premium account |  |  | 11,608,344 |  | 11,608,344
Capital redemption reserve |  |  | 30 |  | 30
Profit and loss account |  |  | (13,987,599) |  | (11,591,150)
|  |  | (2,171,662) |  | 224,787
The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 11 March 2026.
G Jackson
Director
The notes on pages 4 to 16 form part of these financial statements. Page 2
ORCHA HEALTH LIMITED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2025
| Called up share capital | Share premium account | Capital redemption reserve | Profit and loss account | Total equity
| £ | £ | £ | £ | £
At 1 July 2023 (as previously stated) | 6,026 | 8,909,825 | 30 | (8,471,361) | 444,520
Prior year adjustment - correction of error | - | - | - | 40,010 | 40,010
At 1 July 2023 (as restated) | 6,026 | 8,909,825 | 30 | (8,431,351) | 484,530
Comprehensive income for the year |  |  |  |  |
Loss for the year (as restated) | - | - | - | (3,159,799) | (3,159,799)
Total comprehensive income for the year | - | - | - | (3,159,799) | (3,159,799)
Contributions by and distributions to owners |  |  |  |  |
Shares issued during the year | 201,537 | 2,698,519 | - | - | 2,900,056
At 1 July 2024 (as previously stated) | 207,563 | 11,608,344 | 30 | (11,728,269) | 87,668
Prior year adjustment - correction of error | - | - | - | 137,119 | 137,119
At 1 July 2024 (as restated) | 207,563 | 11,608,344 | 30 | (11,591,150) | 224,787
Comprehensive income for the year |  |  |  |  |
Loss for the year | - | - | - | (2,396,449) | (2,396,449)
Total comprehensive income for the year | - | - | - | (2,396,449) | (2,396,449)
Total transactions with owners | - | - | - | - | -
At 30 June 2025 | 207,563 | 11,608,344 | 30 | (13,987,599) | (2,171,662)
| The notes on pages 4 to 16 form part of these financial statements.
Page 3
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
1. | General information
The company is a private company limited by shares, which is incorporated under the Companies Act 2006 and registered in England (no. 08927511). The address of the registered office is The Innovation Centre, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Warrington, WA4 4FS. The company is the parent company of a small group of companies; it is exempt from producing consolidated accounts. These financial statements present information about the company as an individual undertaking. The principal activity of the company is that of review health and care applications and providing solutions to healthcare organisations to help deliver the best applications to their patients. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The following principal accounting policies have been applied:
| 2.2 | Going concern
These accounts show a year consisting mostly of development costs in relation to the company's core offering. The shareholders have agreed to fund the business going forward so that the company can meet lliabilities as they fall due. Therefore, the accounts have been prepared on a going concern basis. Page 4
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 2.Accounting policies (continued)
| 2.3 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
| 2.4 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.5 | Operating leases: the Company as lessee
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term. Page 5
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 2.Accounting policies (continued)
| 2.6 | Research and development
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years. If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
| 2.7 | Government grants
Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income. Grants of a revenue nature are recognised in the Statement of comprehensive income in the same period as the related expenditure.
| 2.8 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.9 | Borrowing costs
All borrowing costs are recognised in profit or loss in the year in which they are incurred.
| 2.10 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds. Page 6
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 2.Accounting policies (continued)
| 2.11 | Taxation
Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.
| 2.12 | Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years. The estimated useful lives range as follows:
|  |  |  | Development expenditure | - | 3 | years
| 2.13 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis:
|  |  |  | L/Term Leasehold Property | - | 20% straight line
|  |  |  | Office equipment | - | 25% straight line
|  |  |  | Computer equipment | - | 33% straight line
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.14 | Valuation of investments
Investments in subsidiaries are measured at cost less accumulated impairment. Page 7
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 2.Accounting policies (continued)
| 2.15 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.16 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.17 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
| 2.18 | Financial instruments
The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments. Other financial assets Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment. Page 8
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 2.Accounting policies (continued)
| 2.18 | Financial instruments (continued)
Impairment of financial assets At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate. If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss. Basic financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities. Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest rate method. Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. Other financial instruments Derivatives, including forward exchange contracts, futures contracts and interest rate swaps, are not classified as basic financial instruments. These are initially recognised at fair value on the date the derivative contract is entered into, with costs being charged to the profit or loss. They are subsequently measured at fair value with changes in the profit or loss. Debt instruments that do not meet the conditions as set out in FRS 102 paragraph 11.9 are subsequently measured at fair value through the profit or loss. This recognition and measurement would also apply to financial instruments where the performance is evaluated on a fair value basis as with a documented risk management or investment strategy. Page 9
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 2.Accounting policies (continued)
| 2.18 | Financial instruments (continued)
Derecognition of financial instruments Derecognition of financial assets Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained. Derecognition of financial liabilities Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.
3. | Employees
| The average monthly number of employees, including directors, during the year was 36 (2024 - 65).
Page 10
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
4. | Intangible assets
|  | Devt. expenditure
|  | £
| Cost |
| At 1 July 2024 | 4,909,928
| Additions | 643,351
| At 30 June 2025 | 5,553,279
| Amortisation |
| At 1 July 2024 | 3,001,665
| Charge for the year on owned assets | 1,273,423
| At 30 June 2025 | 4,275,088
| Net book value |
| At 30 June 2025 | 1,278,191
| At 30 June 2024 | 1,908,263
Page 11
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
5. | Tangible fixed assets
|  | L/Term Leasehold Property | Office equipment | Computer equipment | Total
|  | £ | £ | £ | £
| Cost or valuation |  |  |  |
| At 1 July 2024 | 301,347 | 5,518 | 41,318 | 348,183
| Disposals | (301,347) | (5,518) | - | (306,865)
| At 30 June 2025 | - | - | 41,318 | 41,318
| Depreciation |  |  |  |
| At 1 July 2024 | 105,471 | 5,518 | 30,505 | 141,494
| Charge for the year on owned assets | 30,135 | - | 8,905 | 39,040
| Disposals | (135,606) | (5,518) | - | (141,124)
| At 30 June 2025 | - | - | 39,410 | 39,410
| Net book value |  |  |  |
| At 30 June 2025 | - | - | 1,908 | 1,908
| At 30 June 2024 | 195,876 | - | 10,813 | 206,689
6. | Fixed asset investments
|  | Investments in subsidiary companies
|  | £
| Cost or valuation |
| At 1 July 2024 | 918
| At 30 June 2025 | 918
Page 12
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
7. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Due after more than one year |  |
| Amounts owed by group undertakings | 526,728 | 442,447
|  | 526,728 | 442,447
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Due within one year |  |
| Trade debtors | 48,872 | 191,018
| Amounts owed by group undertakings | 20,523 | -
| Other debtors | - | 172
| Prepayments and accrued income | 5,966 | 173,751
|  | 75,361 | 364,941
8. | Cash and cash equivalents
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Cash at bank and in hand | 42,197 | 58,443
| Less: bank overdrafts | (3,865) | (7,095)
|  | 38,332 | 51,348
Page 13
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
9. | Creditors: Amounts falling due within one year
|  |  |  |  |  | As restated
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Bank overdrafts | 3,865 | 7,095
| Bank loans | 10,020 | 10,020
| Trade creditors | 260,940 | 389,979
| Amounts owed to group undertakings | - | 19,261
| Other taxation and social security | 54,878 | 282,106
| Other creditors | 3,092,767 | 1,408,957
| Accruals and deferred income | 673,820 | 628,684
|  | 4,096,290 | 2,746,102
10. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Bank loans | 675 | 10,813
|  | 675 | 10,813
11. | Loans
| Analysis of the maturity of loans is given below:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Amounts falling due within one year |  |
| Bank loans | 10,020 | 10,020
| Amounts falling due 1-2 years |  |
| Bank loans | 675 | 10,020
| Amounts falling due 2-5 years |  |
| Bank loans | - | 793
|  | 10,695 | 20,833
Page 14
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
12. | Financial instruments
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Financial assets |  |
| Financial assets measured at fair value through profit or loss | 42,197 | 58,443
| Financial assets measured at fair value through profit or loss comprise of cash at bank and in hand.
13. | Prior year adjustment
Work was undertaken by employees of Orcha Health Limited prior to 30th June 2023 and in the year to 30th June 2024, the benefit of which accrued to the Company’s subsidiary undertaking, Orcha Health BV as the appropriate re-charges were not processed and recognised in these periods by Orcha Health Limited. The total amounts which were not re-charged amounted to £137,119. These amounts have now been adjusted as follows:- • Re-charges relating to periods up to 30th June 2023 (reducing staff salaries) £40,010 • Re-charges relating to periods up to 30th June 2023 (reducing staff salaries) £97,109 • Impact on the Opening Net Asset position as 1st July 2023 £40,010 • Impact on the Opening Net Asset position as 1st July 2024 £137,119
14. | Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £103,063 (2024 - £319,426). Contributions totalling £12,388 (2024 - £18,924) were payable to the fund at the balance sheet date and are included in creditors. Page 15
ORCHA HEALTH LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
15. | Commitments under operating leases
| At 30 June 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Not later than 1 year | 28,719 | 114,106
| Later than 1 year and not later than 5 years | 1,274 | 29,993
|  | 29,993 | 144,099
16. | Related party transactions
|  | 2025 | As restated 2024
|  | £ | £
| Amount due to a director | 1,539,562 | 634,050
| Amounts due to a shareholder | 1,539,357 | 634,050
| Amount due to a subsidiary | - | 19,261
| Amount due from subsidiary | 547,251 | 442,447
| Services received from related parties | 20,665 | 36,819
| Sale of office equipment to a related party | 12,500 | -
17. | Controlling party
There is no ultimate controlling party.
Page 16